Heart failure (HF) with preserved ejection fraction, hypertension, valvular heart disease, lower quality-oflife scores, and older age are also more likely in women than in men presenting with AF. 6 For reasons that may be related to cultural or sex bias, women with AF are diagnosed later in their disease course than in men, and they may be referred less frequently to specialized centers or clinics for the management of their arrhythmia. 7 
Treatment and Outcomes
Of the various complications of AF, thromboembolic stroke is the most devastating. AF has been implicated in at least 25% to 30% of all ischemic strokes. 8 Until recently, clinical thromboembolic risk prediction scores for AF did not include sex as a variable. However, retrospective analyses have consistently demonstrated that female sex, especially in the setting of other risk factors, is associated with a higher risk of thromboembolic events compared with male sex. 9 For this reason, the current US and European guidelines advocate for the use of the CHA 2 DS 2 -VASc risk scoring system to assess thromboembolic risk in patients with AF with inclusion of female sex as a risk factor. 10, 11 Studies on the sex differences in the rates of utilization of anticoagulant therapy show mixed results. Elderly women with new-onset AF were less likely to be prescribed anticoagulation than elderly men in 1 study, and this difference was not explained by differences in stroke risk. 12 Elderly women have been identified as a high-risk group in this context. 12 However, a more recent study specifically evaluating sex differences in rates of anticoagulation use for stroke prophylaxis showed no difference. 13 Subsequently, a larger study evaluating the predictors of antithrombic versus anticoagulant therapy demonstrated an association between male sex and anticoagulant use.
14 Nonetheless, it seems that anticoagulation is equally effective for stroke prophylaxis in both sexes. 15 Managing patients with AF requires a strategy of rhythm or rate control. Sex differences in the utilization patterns of either strategy seem to be inconsistent in contemporary studies. Women were less likely to have electric cardioversion and more likely to receive rate control in 1 recent analysis. 6 In another analysis of Medicare beneficiaries with newly diagnosed AF, women were more likely to receive rate and rhythm control compared with men. Utilization differences in these studies could possibly be explained by differences in the study population age, access to care, and symptoms. 16 When a rhythm control strategy is used, women who are prescribed antiarrhythmic drugs (AAD) may be at higher risk for proarrhythmia than men. Female sex is associated with a significantly increased risk of polymorphic ventricular tachycardia (VT) in the setting of a prolonged QT interval (torsades de pointes) with the use of the class III antiarrhythmic sotalol. 17 Studies of other class III AADs are consistent. 18 Women constitute a majority of the cases of acquired long-QT syndrome (LQTS) and torsades de pointes independent of other comorbidities. It is possible that the longer intrinsic QT interval in women compared with men predisposes to a higher incidence of proarrhythmia from QT-prolonging drugs. The hormonal milieu during different time periods in the menstrual cycle may alter the risk of proarrhythmia in women treated with class III AADs. For example, the degree of QTc prolongation with ibutilide is inversely related to progesterone levels during the menstrual cycle and may predispose to higher arrhythmic risk during menses and the ovulatory phase compared with the luteal phase. Although current guidelines do not mention a sex-based approach to AADs, the data mentioned suggests that a sex-based approach is warranted and may favor class IC medications as initial AAD therapy over class III AAD in women with symptomatic AF. 19 Catheter ablation for AF as a rhythm control strategy is a class I recommendation for those patients with symptomatic paroxysmal AF refractory to at least 1 antiarrhythmic medication. 10 Sex differences in the uti- AT indicates atrial tachycardia; AVNRT, atrioventricular node reentrant tachycardia; AVRT, atrioventricular reentrant tachycardia; BrS, Brugada syndrome; CV, cardiovascular; ER, early repolarization; FVT, fascicular ventricular tachycardia; ICD, implantable cardioverter defibrillator; ICM, ischemic cardiomyopathy; IHD, ischemic heart disease; LBBB, left bundle branch block; LMIC, lower-and middle-income countries; LQTS, long-QT syndrome, PEA, pulseless electric activity; RVOT, right ventricular outflow tract; SCA, sudden cardiac arrest; SHD, structural heart disease; SVT, supraventricular tachycardia, VA, ventricular arrhythmias; VF, ventricular fibrillation; VT, ventricular tachycardia, and WPW, Wolff-Parkinson-White.
lization of catheter ablation has been consistently demonstrated in multiple studies. Women with AF are less likely to be referred for catheter ablation than men. 20 Women are also referred later in the course of AF than men. 7 These findings seem to be independent of age, hospitalization, and insurance status and has persisted over many years. 21 Success rates of catheter ablation for AF may also vary between the sexes. Catheter ablation for paroxysmal AF provides better long-term arrhythmia-free survival compared with ablation for persistent or longstanding persistent AF. There may be an association between delayed referrals and a preponderance of later stage AF among women undergoing ablation; however, this remains to be confirmed. Studies comparing AF catheter ablation outcomes between men and women show mixed results. One study did not show a significant sex difference in success rates of catheter ablation for AF. 22 More contemporary data suggest the opposite. Female sex was associated with higher long-term recurrence rates after both radiofrequency and cryoballoon catheter ablation of AF. 23 The largest randomized clinical trial comparing radiofrequency ablation to cryoballoon ablation for paroxysmal AF included 39% women. There was no difference in long-term outcomes between the 2 techniques among all patients; however, stratification based on sex was not performed. 24 Contemporary data suggest that complication rates with catheter ablation of AF/AFL may be different between men and women. Female sex is associated with a higher incidence of complications with catheter ablation of AF compared with male sex and is a predictor of complications in both univariate and multivariate analyses. 22 Recent studies demonstrate that women undergoing first-time catheter ablation had a higher incidence of in-hospital complications, especially access-site bleeding and hematoma. 23 Women are consistently under-represented in AF catheter ablation trials, and this needs to be addressed in future studies. Sex differences with newer catheter-based techniques will also need to be reviewed to further our understanding of sex differences with ablation of AF.
Implications
Treatment of AF requires a comprehensive and individualized approach to the patient. Men and women with AF differ in their symptoms, referral patterns, comorbidities, response to treatments, and outcomes. The contemporary approach to management of AF should, therefore, reflect the sex differences mentioned above. The Table displays a contemporary approach to AF in women considering the clinical and utilization differences among the sexes. Novel suggestions for assessment and treatment are based on clinical studies showing sex differences in safety and outcomes in AF.
OTHER SUPRAVENTRICULAR TACHYCARDIAS Atrioventricular Nodal Reentry Tachycardia
Atrioventricular nodal reentry tachycardia (AVNRT) is the most common form of non-AF/AFL supraventricular tachycardia (SVT), accounting for ≈50% of all cases. 27 Women are affected twice as often as men and exhibit a bimodal distribution, with women presenting at an earlier age than men. 28 Sex differences in the basic electrophysiological properties of the normal atrioventricular node provide clues to the mechanisms by which these differences arise. Women demonstrate shorter atrioventricular block cycle lengths, shorter antegrade atrioventricular node slow pathway effective refractory periods, shorter tachycardia cycle lengths, and similar atrioventricular node fast pathway effective refractory periods compared with men. 29 This suggests that women, more so than men, can maintain robust antegrade atrioventricular node slow pathway conduction thereby promoting reentrant tachycardia, possibly explaining their higher prevalence of AVNRT. Also, women with the atypical form of AVNRT demonstrate shorter retrograde slow pathway effective refractory periods than their male counterparts. 30 Acute success rates and long-term recurrences are similar among the sexes. Hormonal changes during the menstrual cycle in premenopausal women may impact the frequency of SVT.
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Pre-Excitation/Wolff-Parkinson-White Syndrome and Atrioventricular Reentry Tachycardia
Ventricular pre-excitation and atrioventricular reentry tachycardia occur more frequently in men than in women. 28 Interestingly, the location of accessory pathways (AP) may be different among men and women. An investigation of AP location by age and sex showed that women were more likely to have a tricuspid annular AP. 32 Manifest AP conduction is seen more often in men; however, there is equal distribution of concealed APs among men and women. 33 
Atrial Tachycardia
Atrial tachycardia, the least common of all SVTs, has a female preponderance. 34 The largest study of sex differences in focal atrial tachycardias demonstrated that men were more likely to be older, have more cardio-vascular comorbidities, and have a lower incidence of other SVTs than women. The anatomic origin of atrial tachycardia and acute and long-term success rates after catheter ablation were not different among men and women. 35 
IMPLICATIONS IN THE TREATMENT OF OTHER SVTS
Approaches to the treatment of SVT in men and women should be tailored to the sex differences observed. A detailed clinical history and review of triggers for SVT should be obtained especially in premenopausal women who may have a cyclic trend of tachycardia throughout the ovarian cycle. If electrophysiology study and catheter ablation is pursued, a strategy of scheduling the patient during a period of the ovarian cycle where SVT occurs more frequently may be useful. AVNRT will be the most common cause of SVT in women, and a discussion of risk and benefits of catheter ablation should be tailored to include the risks of ablation for AVNRT (ie, risk of atrioventricular block) more so than other arrhythmias.
SUDDEN CARDIAC ARREST AND VENTRICULAR ARRHYTHMIAS
The burden of sudden cardiac arrest (SCA) in men compared with that in women has changed over time. In earlier analyses, men seemed to be 3 times more likely to experience SCA than women. 36 Framingham study data also showed that women with coronary artery disease or risk factors had a lower incidence of SCA compared with their male counterparts. 37 Contemporary data suggests that the sex gap has narrowed somewhat but is still significant. 38 Men comprise the majority of cases of SCA with severe left ventricular (LV) systolic dysfunction, whereas there is no apparent difference in the sex distribution among those with normal LV systolic function. 39 Overall, the proportion of SCA caused by ventricular fibrillation (VF) has declined in the past 2 decades. 40 However, the proportion of pulseless electric activity has increased, and female sex is independently associated with pulseless electric activity. 41 The lower proportion of VF versus pulseless electric activity observed in contemporary studies may be explained by a lower rates of mortality from coronary artery disease and higher mean LV ejection fraction in women with SCA compared with men. 42 Women who present with a shockable rhythm like VF may have improved resuscitation and survival rates compared with men, resulting in equivalent survival rates despite a higher proportion of pulseless electric activity in women. 43 The sex differences observed for SCA may also vary with the age. A recent nationwide study demonstrated that the rates of SCA in young men were twice that of young women. There was no difference in the rates of explained (autopsy-proven cardiovascular disorder) and unexplained SCA, arrhythmic death, and death during sleep. Men had a nonsignificant trend toward a higher proportion of SCA during moderate-to high-intensity exercise compared with women. 44 In the 35-to 44-year age group, women have higher rates of unexplained SCA compared with men. 45 Older age may diminish the sex differences regarding traditional coronary artery disease risk factors and underlying coronary disease. Furthermore, nonischemic, structural causes of SCA caused by VF may be more prevalent in women. Overall, women are significantly less likely than men to have a diagnosis of LV dysfunction or coronary artery disease before SCA. 46 Improvements of SCA risk stratification for prevention of SCA may have even higher importance for women.
Ventricular Arrhythmias in Structural Heart Disease
Ischemic heart disease is the most common form of structural heart disease in the world. 47 Ischemic heart disease is more common in men than in women, but the demonstration of sex differences in the incidence of ventricular arrhythmias (VAs) in patients with ischemic heart disease has been limited by a paucity of data from female cohorts. Studies on outcomes from implantable cardioverter defibrillator (ICD) therapy trials for primary prevention of SCD in ischemic heart disease have shed some light onto this subject and suggest that women with ischemic cardiomyopathy (ICM) may be less susceptible to VAs compared with men. Women had a lower risk of appropriate ICD therapy for VT/VF compared with men in 1 study but only 20% of the subjects were women. 48 In an analysis of sex differences in patients with ICM and prior myocardial infarction, women were less likely to have inducible sustained VAs and were more likely to be older, have more HF, and have more recent infarcts compared with men. 49 Women with ICM treated with ICD therapy are less likely to experience VT/VF and death compared with men. This difference is mainly driven by the event rates of VT/VF suggesting that women may experience more nonarrhythmic death than men with ICM. 50 Similar to ICM, the assessment of sex differences in the risk of sustained VAs in nonischemic cardiomyopathy (NICM) is limited by a paucity of data in women. However, in many landmark studies and meta-analyses of trials evaluating primary prevention ICD therapy, women comprise a higher proportion of the NICM cohort than the ICM cohort. 51 Contemporary data suggests that women with NICM treated with ICD therapy have a lower cumulative incidence of treated VT/VF compared with men. 50 Women may have a different susceptibility to sustained VAs after adjusting for clinical and electrophysiological factors associated with VAs in both ICM and NICM. This may be because of sex differences in ventricular repolarization, autonomic tone, ion channel function, intracellular calcium handling, and excitation-contraction coupling.
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Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
Arrhythmogenic right ventricular cardiomyopathy/ dysplasia is an inherited disease with progressive fibro-fatty replacement of ventricular myocardium. 53 A common complication and presentation of arrhythmogenic right ventricular cardiomyopathy/dysplasia is VA or sudden cardiac death. An analysis of patients with confirmed arrhythmogenic right ventricular cardiomyopathy/ dysplasia (58% male) showed that male sex was a risk factor for VAs at a follow-up period of up to 5.8 years. 54 Strenuous exercise has also been associated with higher arrhythmic risk, and it is possible that the sex differences seen are partly because of higher prevalence of strenuous or athletic activity in young men compared with young women. 55 It is interesting to note in this cohort that no subject had an arrhythmic event before the age of 16 years, which may potentially implicate sex hormones in the pathogenesis of life-threatening VAs in arrhythmogenic right ventricular cardiomyopathy/dysplasia.
Cardiac Sarcoidosis
Cardiac sarcoidosis can be present in up to 25% of patients with systemic sarcoidosis, an uncommon granulomatous disease that can involve virtually every organ system. Globally, the highest prevalence of disease is in middle-aged Northern European and black women. Familial clustering is not uncommon and suggests a genetic component in certain cases. 56 VAs may be the first presenting sign of systemic disease with cardiac involvement or isolated cardiac sarcoidosis. Although the prevalence of sarcoidosis seems to be higher in women than in men, 57 differences in the incidence and outcomes of VAs in males and females have not been described. Interestingly, although there is a higher prevalence of disease among women, studies of catheter ablation of VAs caused by cardiac sarcoidosis mostly report findings in male subjects. 58 Whether female sex protects against scar-related arrhythmogenesis in this progressive disease is a question that would require further evaluation in large multicenter analyses.
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy is the most common of all the inherited cardiomyopathies and is characterized by disorganized myocardial hypertrophy and fibrosis that affects men and women equally. 59 Hypertrophic cardiomyopathy is the most common cause of SCD in the young, especially male athletes. It seems that once hypertrophic cardiomyopathy is diagnosed, the risk of SCD is similar among men and women. In a large study of hypertrophic cardiomyopathy patients from Italy and the United States, female patients were noted to be on average older, have more outflow tract obstruction, and have more symptoms than men. Women had a poorer prognosis with more rapid progression toward death from HF or stroke. SCD and mortality was similar among men and women with hypertrophic cardiomyopathy in this group.
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ICD Therapy Utilization
Sex differences have been described in the utilization of ICD therapy in those patients with structural heart disease, who are at risk for or have had VAs or SCD. ICD utilization was analyzed in a Medicare population from 1991 to 2005 and demonstrated that men were more likely to receive an ICD than women. This was consistent in both primary and secondary prevention indications for ICD implantation, did not significantly change with time, and was independent of age. The reason for the sex difference and the possibility of a sex disparity is unclear. For example, as mentioned by the authors, the large difference in the secondary prevention cohort may not be explained by the small sex differences of reversible causes of VT/VF, and, therefore, this may represent a disparity. 61 Factors that may contribute to this difference include the possibility of differences in the perceived net clinical benefit of ICD implantation, perception of competing comorbid conditions, and underrepresentation of women in most primary prevention ICD trials. Nonetheless, sex differences in counseling for and utilization of primary prevention ICD therapy in the age of guideline-directed HF therapy have persisted.
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Mortality in Recipients of ICDs
There has been considerable research into the sex differences in mortality among recipients of ICDs. As mentioned, all the major primary prevention ICD trials were not adequately powered to detect sex-related differences in outcomes. Meta-analyses of primary prevention ICD trials have shown mixed results. Mortality in women was comparable to men enrolled in a primary prevention ICD trial of patients with ICM. 63 In a meta-analysis of 5 major primary prevention ICD trials, a statistically significant reduction in mortality was observed in men with HF and reduced LV ejection fraction (hazard ratio, 0.78) but not in women (hazard ratio, 1.01). 64 Another meta-analysis with a larger proportion of women and inclusion of a cardiac resynchronization therapy trial demonstrated similar mortality rates among men and women with ICDs; however, there was less ICD therapy for VT/VF in women compared with men. 65 This again suggests that mortality in women with HF and reduced LV ejection fraction may be driven more by nonarrhythmic death. The relative contributions from arrhythmic and nonarrhythmic death in overall mortality in women with HF may also change based on the disease substrate. A recent trial in patients with NICM, HF, and LV ejection fraction ≤35% showed no significant overall mortality benefit with prophylactic ICD implantation, especially in older patients. 66 Sex differences were suggested in a subgroup analysis, but the study was underpowered for this evaluation.
It is likely that multiple factors play a role in the sex differences observed for outcomes of ICD implantation in structural heart disease. These may include effects of sex hormones on the underlying substrate, comorbid associations, and the net gain of an ICD added to adequate guideline-directed therapy in women versus men. If ICD therapy for primary prevention of SCA in patients with NICM does not provide a net clinical benefit compared with ICM, it may be possible that women, who comprise a higher proportion of NICM in most trials, may follow this trend. Future studies should incorporate a larger proportion of women or perform a prespecified analysis to address this issue.
Catheter Ablation of VAs in Structural Heart Disease
Women have been under-represented in most trials of catheter ablation for VT in structural heart disease. In an international registry of patients with structural heart disease referred for VT ablation, women comprised only 13% of the patients. However, compared with men, women had a higher incidence of recurrent VT at 1 year, and this was most pronounced in the ICM group. 67 Male sex may be associated with VT recurrence compared with female sex. 68 A study of patients referred for catheter ablation of VT during the past decade showed that of those with structural heart disease, a higher proportion of women was observed in the nonischemic compared with the ischemic group. 69 It is unclear whether the sex differences identified are attributable to referral patterns or truly reflect a lower incidence of VT and ICD therapies in women because of physiological differences in arrhythmogenesis among men and women with structural heart disease.
VT in Structurally Normal Hearts
Idiopathic VAs include monomorphic VT and frequent ventricular premature beats in the absence of ventricular myocardial pathology. Overall, they represent ≈10% of VAs in clinical practice. 70 These arrhythmias may originate in the right and LV outflow tracts, tricuspid and mitral annuli, midmyocardial or subepicardial areas, or be of fascicular or papillary muscle origin. Right ventricular outflow tract VAs occur more frequently in women than in men. Men have a higher incidence of LV outflow tract, tricuspid and mitral annular, ventricular septal, and nonoutflow tract VAs compared with women. 71, 72 Studies of fascicular VT have been conducted almost exclusively in male patients, suggesting a much higher prevalence of this type of idiopathic reentrant VA in men compared with women.
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FAMILIAL ARRHYTHMIA SYNDROMES
Long-QT Syndrome
LQTSs are inherited genetic disorders caused by monogenic mutations in key ion channels in cardiac myocytes. There is a female preponderance of inherited LQTS. As in the general population, women with LQTS (especially LQTS1 and LQTS2) have on average longer QT intervals than their male counterparts. 74 There is a significant association between longer QT interval duration and risk for cardiac events in patients with LQTS that may explain the difference in cardiac events between adult men and women with this disorder. One of the largest studies of familial LQTS reported an agerelated difference in the risk of cardiac events among men and women, suggesting a role of sex hormones in arrhythmic risk. 75 The complex interplay of sex hormones and age with repolarization currents and the relevance to clinical outcomes in men and women with LQTS is an area that requires further investigation. A strategy toward a more aggressive preventative approach for prepubertal boys with LQTS may be warranted in clinical practice. Pharmacotherapy may be de-escalated later in life given that the arrhythmic risk may be reduced in adult males. 75 However, the same may not be true for women who may have a higher lifetime risk of cardiac events than men, in part because of less QT interval shortening after puberty and more hormonal effects on QT prolongation during the ovarian cycle. In addition, with advancing age, there may be increased use of over-the-counter or prescription QT-prolonging medications that increase the arrhythmic risk in women more than that in men. The sex differences observed in the arrhythmic risk of LQTS patients may have a significant clinical impact in the evaluation and treatment of this patient population.
Brugada Syndrome
Studies on Brugada syndrome (BrS) have demonstrated a preponderance of male subjects with specific clinical characteristics that are different from women. A greater rate of spontaneous type-1 Brugada-pattern electrogram is seen in men compared with women. Men experience syncope, aborted sudden death, and documented VF more frequently than women with BrS. 76 The exact mechanism of the differences observed in men and women with BrS is unclear. The genetics of BrS have not been shown to be a factor in sex differences, with no difference in the distribution of specific gene mutations (most commonly SCN5A) between men and women.
Catecholaminergic Polymorphic VT
Limited data exists to suggest sex differences among patients with catecholaminergic polymorphic VT. This disorder, characterized by a normal baseline ECG and structurally normal heart, is caused by mutations in genes encoding proteins that affect calcium handling in the cardiac myocyte. 77 Young men with cardiac RYR2 (ryanodine receptor 2) mutations were shown to have a higher risk of cardiac events than young women. 78 Genotypic and phenotypic heterogeneity among referrals for catecholaminergic polymorphic VT suggests that men, compared with women, are more likely to be positive for the RYR2 mutation. Because most of the RYR2 mutation-negative patients are women, there is a significant need for novel, sex-specific gene discovery.
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Early Repolarization Syndrome
Early repolarization syndrome is characterized by J-point and ST-segment elevation in at least 2 contiguous ECG leads in the setting of a clinical event such as VF or sudden death. The ECG pattern of early repolarization (global, lateral, or inferior lead involvement) may change the cardiac risk profile for the individual asymptomatic patient. 80 Male sex is strongly associated with the early repolarization ECG pattern, and this pattern is less prevalent with increasing age. 81 There may be some overlap with BrS; hence, both genetic arrhythmia syndromes have a male preponderance, especially in the rates of cardiac events.
CONDUCTION SYSTEM DISEASE
Sex differences have been described in various bradyarrhythmias requiring permanent pacing with respect to physiology, utilization, and implant complications. In retrospective and prospective analyses, women have a higher incidence of sinus node dysfunction and men a higher incidence of atrioventricular node dysfunction. 82 A retrospective analysis of >30 000 patients implanted with a permanent pacemaker demonstrated that women on average presented at an older age than men. 83 Women are more likely to receive single-chamber pacemaker systems. The differences in selection of dual-versus single-chamber pacemakers may not be completely explained by a higher incidence of sinus node dysfunction in women. 84 It remains unclear whether physician bias toward single-chamber systems in the elderly plays a role in these observations.
Complication rates during implantation of cardiac implantable electronic devices also differ between the sexes. Women have higher rates of complications independent of age and type of device implanted. 84 This difference is mainly driven by the higher incidence of pocket hematoma and pneumothorax in women. Inhospital adverse events were significantly higher in women than in men in multivariate analysis of the National Cardiovascular Data Registry database. 85 Higher complication rates may be because of various factors that may include smaller body habitus in women. Longterm outcomes after pacemaker implantation suggest that although women have higher periprocedural morbidity, men have higher mortality independent of age.
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CONCLUSIONS
It is without a doubt that sex differences exist for multiple aspects of a wide variety of cardiac arrhythmias. Sex differences in the incidence, characteristics, and treatment outcomes are clear, but we have an inadequate understanding as to why these differences exist. This is an area that deserves more attention than the sex differences themselves. Other than a few studies of SVT, most prospective trials and studies continue to rely on data obtained from a minority of female subjects. This is the first major issue that needs to be addressed in future investigations. The burden of AF is increasing, and women are recognized as a high-risk group with considerable morbidity and mortality, particularly in the low-and middle-income regions of the world. On a broad healthcare level, our assessment and treatment of patients with AF should have a foundation that incorporates sex differences. Many important questions on sex differences in other arrhythmias remain unanswered. Does referral bias play a role in the rates of women enrolled in VT ablation trials or are women less likely to have VAs as a complication of structural heart disease, particularly ICM? If the latter is true, investigations into the arrhythmogenic properties of scar, the autonomic nervous system, AAD metabolism and effects, and other factors in women with structural heart disease are needed. Disease-based animal models with careful attention to sex as a biological variable could provide insight as well. Device-based therapy outcome in women is an area that also deserves continued exploration. With more contemporary randomized clinical trials reassessing the benefit of ICDs and cardiac resynchronization therapy in heart disease, we anticipate future changes in the guidelines regarding device-based therapy. Our current understanding of the mechanisms by which sex differences exist in cardiac arrhythmias is still at an early stage. Advancing our knowledge of sex differences will benefit individualized patient care and health outcomes for cardiac arrhythmias at a global level.
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